(Press-News.org) Now, the work presented at the 2025 annual EULAR congress in Barcelona adds two important pieces to the puzzle. First, a large-scale real-world study reporting no significantly higher risk of cancer in RA patients treated with JAKi compared to bDMARDs, and second an abstract looking at whether the glucagon-like peptide-1 receptor agonists (GLP-1RA) which are causing waves in many fields including diabetes and obesity might offer cardiovascular protection in RA.
Romain Aymon and colleagues set out to assess the cancer incidence in RA patients treated with JAKi compared to biologic disease-modifying anti-rheumatic drugs (bDMARD), using data from 13 registers. Cancers were linked to treatments within 5 years of cessation or until follow-up loss, death, or study end, whichever came first. Overall they identified 53,169 treatment initiations in 33,127 patients; 219 non-melanoma skin cancers (NMSC) were reported, plus 638 non-NMSC cancers. The crude incidence of non-NMSC cancer was lower for TNFi than both JAKi and bDMARDs with other mechanism of action (OMA), with rates of 2.2, 2.9, and 3.1 per 1000 patient-years. But further statistical analysis found no significant difference in the incidence of either cancer type between JAKi and TNFi, nor between JAKi and OMA.
A sub-analysis was performed on patients aged 50 and older who had at least one cardiovascular risk factor – mimicking the inclusion criteria from ORAL Surveillance. This high-risk cohort made up 39.4% of treatment courses, and showed a higher cancer incidence in each treatment group: 3.2, 4.2, and 4.1 per 1000 patient-years for TNFi, JAKi, and OMA, respectively. But similarly to the overall population, there was no significant difference in the incidence of either cancer type between JAKi and either bDMARD group.
The authors note that further analyses are planned, including additional registries to enhance statistical power and that they will evaluate the cancer incidence across different exposure periods – but in the meantime the findings look reassuring.
Of note, the incidence of keratinocyte cancer – largely comprised of basal cell and squamous cell carcinoma – is increasing in the general population. This could be due to UV light, but immune alteration has also been linked to increased risk – including in people with RA, but largely with data from the pre-biologic era. New work has set out to assess the risk of keratinocyte cancer in modern RA patients initiating treatment with b/tsDMARDs, including the risk of a second keratinocyte cancer. 21,121 people were identified from the Swedish Rheumatology Quality Register. Overall, 94 keratinocyte cancers were identified in people starting a JAKi, 407 with OMA, and 628 with a TNFi. When compared to TNFi, the hazard ratio for a keratinocyte cancer was 1.72 with JAKi and 0.81 with OMA, Among RA patients with a history of keratinocyte cancers, the hazard ratio for a second diagnosis was 2.76 for JAKi versus TNFi, and 1.54 for OMA versus TNFi.
Presenting the work, Viking Huss said “these findings suggest that people with RA treated with a JAKi have a higher incidence of a first keratinocyte cancer, primarily driven by basal cell carcinoma. Additionally – although based on a limited number of events – we saw a higher incidence of a second cancer of this type with JAKi compared to TNFi.”
These findings support the notion that skin examination would be beneficial in this population, and skin cancer risks with JAKi treatment should be monitored.
It is well-known that as well as increased cancer risks, people with RA are prone to cardiovascular complications, and in ORAL Surveillance JAKi were associated with adverse cardiovascular events.1 Conversely, GLP-1RA have demonstrated possible cardioprotective effects in other patient populations, with some agents now specifically approved for reducing cardiovascular risk.
Asmaa Beltagy presented findings from a retrospective analysis of two cohorts of RA patients over the age of 40. All 2,449 patients were on JAKi, but one group subsequently initiated GLP-1RA, while the other group did not. The work assessed primary outcomes occurring within 5 years, including the incidence of acute coronary syndromes, cerebral infarction, acute peripheral arterial thrombosis, deep venous thrombosis, and overall arterial events.
The results show that patients taking a GLP-1RA had a significantly lower risk of acute coronary syndromes and deep venous thrombosis, with a trend towards a lower risk of acute cerebral infarction and peripheral arterial disease events, although the difference was not statistically significant. The overall incidence of cardiovascular events was significantly lower in GLP-1RA group. A survival analysis showed comparable probabilities between the two groups for all studied outcomes, with no significant difference in median survival.
These findings underscore the potential of GLP-1RA to reduce certain CV risks in people with RA being treated with JAKi. However, not all effects were significant, and there remains a need for further research to validate the results.
Source
Aymon R, et al. Cancer incidence among rheumatoid arthritis patients treated with JAK-inhibitors compared to bDMARDs: data from an international collaboration of registers (the "JAK-pot" study). Presented at EULAR 2025; OP0232. Ann Rheum Dis 2025; DOI: 10.1136/annrheumdis-2025-eular.A21.
Huss V, et al. Rheumatoid arthritis, non-TNFi bDMARDs and JAKi - risks of keratinocyte cancer. Presented at EULAR 2025; OP0067. Ann Rheum Dis 2025; DOI: 10.1136/annrheumdis-2025-eular.B130.
Beltagy A, et al. GLP1 agonists mitigate the risk of cardiovascular events in Rheumatoid Arthritis patients treated with JAK inhibitors. Presented at EULAR 2025; OP0069. Ann Rheum Dis 2025; DOI: 10.1136/annrheumdis-2025-eular.B1457.
References
1. Ytterberg SR, et al. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med 2022;386(4):316–26. DOI: 10.1056/NEJMoa2109927.
2. Smolen JS, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease- modifying antirheumatic drugs: 2022 update. Ann Rheum Dis 2023;82:3–18. DOI: 10.1136/ard-2022-223356.
About EULAR
EULAR is the European umbrella organisation representing scientific societies, health professional associations and organisations for people with rheumatic and musculoskeletal diseases (RMDs). EULAR aims to reduce the impact of RMDs on individuals and society, as well as improve RMD treatments, prevention, and rehabilitation. To this end, EULAR fosters excellence in rheumatology education and research, promotes the translation of research advances into daily care, and advocates for the recognition of the needs of those living with RMDs by EU institutions.
Contact
EULAR Communications, communications@eular.org
Notes to Editors
EULAR Recommendations
EULAR School of Rheumatology
EULAR Press Releases
END
New safety data for JAK inhibitors
2025-06-12
ELSE PRESS RELEASES FROM THIS DATE:
Impact of education and social factors in RMD
2025-06-12
Social determinants of health (SDH), such as socioeconomic status and educational background are factors that are increasingly recognised as critical contributors to health outcomes in chronic diseases. Understanding how certain factors impact different RMDs is important, and new research into this for both systemic lupus erythematosus (SLE) and inflammatory arthritis was presented at the 2025 annual EULAR congress in Barcelona.
SLE is a chronic autoimmune disease that exhibits considerable clinical heterogeneity, and is associated with substantial morbidity ...
Zinc–iodine battery with outstanding stability now a reality
2025-06-12
Researchers at the University of Adelaide have developed a new dry electrode for aqueous batteries which delivers cathodes with more than double the performance of iodine and lithium-ion batteries.
“We have developed a new electrode technique for zinc–iodine batteries that avoids traditional wet mixing of iodine,” said the University of Adelaide’s Professor Shizhang Qiao, Chair of Nanotechnology, and Director, Centre for Materials in Energy and Catalysis, at the School of Chemical Engineering, who led the team.
“We mixed active materials as ...
Capturing the fleeting transformation of perovskite nanomaterials under light
2025-06-12
A team at the Institute for Basic Science (IBS) Center for Molecular Spectroscopy and Dynamics (CMSD) — led by Director CHO Minhaeng (Professor of Chemistry, Korea University) and Professor YOON Tai Hyun (Department of Physics, Korea University) — has developed a powerful new spectroscopic technique that enables real-time tracking of how perovskite nanomaterials change under light.
The technique, called asynchronous and interferometric transient absorption spectroscopy (AI-TA), provides ultrafast measurements of excited-state dynamics and structural transformations in light-responsive materials. It overcomes major limitations ...
United Nations launches global call-to-action to accelerate social progress through AI-powered virtual worlds
2025-06-12
Turin, Italy — 12 June 2025 — Eighteen UN entities joined forces today during the 2nd UN Virtual Worlds Day to urge governments, civil society, academia, and the private sector to harness the transformative potential of AI-powered virtual worlds to drive development that works for all.
The call-to-action outlines 12 priorities—from expanding connectivity to promoting responsible use of emerging technologies—in order to ensure that no one is left behind in the fast-evolving digital era.
The two-day global forum brought together leaders, innovators, and youth changemakers from around the world to spotlight how emerging technologies—from ...
Novel drug combination is safe and benefits people with acute myeloid leukemia who have a specific genetic profile
2025-06-12
A combination therapy that adds a recently approved drug to the current standard of care for newly diagnosed acute myeloid leukemia (AML) showed high rates of complete remission in an early-phase clinical trial conducted at UNC Lineberger Comprehensive Cancer Center and 11 other sites nationwide.
The trial findings will be published in the Journal of Clinical Oncology (JCO) and presented at the European Hematology Association Congress in Milan, Italy, both on June 12. Joshua F. Zeidner, MD, associate professor of medicine ...
Sleep apnea more common than previously known in female athletes
2025-06-12
According to a new study, presented at the American College of Cardiology (ACC) Care of the Athletic Heart 2025 conference, sleep apnea may be more prevalent in younger female athletes than previously believed, especially among female athletes with higher levels of training. While obstructive sleep apnea has been observed in younger male athletes, the prevalence in female athletes and the association with cardiovascular risk is largely unknown.
Obstructive sleep apnea (OSA) is the most common sleep-related breathing disorder, impacting about 18 million Americans, and is prevalent in both men and women. It occurs when the throat muscles relax and ...
Study: Eating more fruits and veggies could help you sleep better
2025-06-12
From counting sheep to white noise and weighted blankets, people have tried innumerable ways to get a good night’s sleep. Sleep disruptions can have far-reaching negative consequences, impacting cardiovascular and metabolic health, memory, learning, productivity, mood regulation, interpersonal relationships and more.
It turns out that an important tool for improving sleep quality may have been hiding in plain sight…in the produce aisle. A new study led by researchers at the University of Chicago Medicine and Columbia University found that eating more fruits and vegetables during the day was associated with sleeping more soundly later that same ...
Intravenous fluid study illustrates powerful, efficient approach for comparative clinical trials
2025-06-12
A clinical trial led by researchers at The Ottawa Hospital and the University of Ottawa and published in the New England Journal of Medicine illustrates a powerful and efficient approach for comparing different standard treatments. The FLUID trial compared two intravenous fluids that have been commonly used for decades in hospitalized patients: normal saline and Ringer's lactate. Many millions of litres of these fluids are used every year in Canada alone, and there is no strong evidence favouring one over the other across the hospital.
Unlike a traditional trial, which would randomly assign each patient ...
Lithium supply will fall short of growing electric vehicle demand through 2029
2025-06-12
In a study publishing June 12 in the Cell Press journal Cell Reports Sustainability, researchers conducted the most comprehensive analysis to date on lithium supply and demand in China, Europe, and the USA. Despite that domestic lithium production in some of these regions could grow as much as 10 times by 2030, it would still fall short of the soaring demand for electric vehicles (EVs) without expanding imports or technological innovation.
“Lithium today is as important as gasoline in the industrial revolution,” says author Qifan Xia of East China Normal University in Shanghai. “While lithium reserves are substantial around the world, they are distributed ...
Humans have unique breathing “fingerprints” that may signal health status
2025-06-12
Your breath is one of a kind. A study published June 12 in the Cell Press journal Current Biology demonstrated that scientists can identify individuals based solely on their breathing patterns with 96.8% accuracy. These nasal respiratory “fingerprints” also offer insights into physical and mental health.
The research stemmed from the lab’s interest in olfaction, or the sense of smell. In mammals, the brain processes odor information during inhalation. This link between the brain and breathing led researchers to wonder: since every brain is unique, wouldn’t ...